Actively Recruiting
BMI-Driven Tolerability and Efficacy of Entresto in Heart Failure Patients
Led by Lithuanian University of Health Sciences · Updated on 2024-06-03
340
Participants Needed
1
Research Sites
68 weeks
Total Duration
On this page
Sponsors
L
Lithuanian University of Health Sciences
Lead Sponsor
S
Sligo General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to determine if patients with higher BMI can tolerate higher doses of Entresto (sacubitril/valsartan) and experience better symptomatic and functional outcomes compared to patients with lower BMI.
CONDITIONS
Official Title
BMI-Driven Tolerability and Efficacy of Entresto in Heart Failure Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 and older
- Diagnosed with heart failure with reduced ejection fraction (HFrEF) (LVEF 35%)
- Na ve to Entresto therapy or willing to switch from previous ACE inhibitor/ARB therapy
- Ability to provide informed consent
You will not qualify if you...
- Severe renal or hepatic impairment (e.g., eGFR < 30 mL/min/1.73m, severe liver disease)
- History of angioedema
- Pregnant or breastfeeding women
- Patients with malignancies or other severe comorbid conditions
- Non-compliance with medication regimen
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital of Lithuanian University of Health Sciences Kaunas Clinics
Kaunas, Lithuania, LT-50161
Actively Recruiting
Research Team
A
Ali Aldujeli, MD., MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here